Evidence map›Paper›PMID 41559396›Full record

ArticleBone marrow transplantation2026

Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with cutaneous T-cell lymphoma.

Isabelle Krämer, Laila König, Arne Brecht, Jessica C Hassel, Thomas Luft, Ute Hegenbart, Tanja Eichkorn, Peter Stadtherr, Carsten Müller-Tidow, Peter Dreger

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Isabelle KrämerInternal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany. isabelle.kraemer@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-1667-4109
Laila KönigDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Arne BrechtInternal Medicine V, Hematology, Oncology and Palliative Medicine, Klinikum Darmstadt, Darmstadt, Germany.
Jessica C HasselHeidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.
Thomas LuftInternal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-0387-1640
Ute HegenbartInternal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-1917-6746
Tanja EichkornDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Peter StadtherrInternal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Carsten Müller-TidowInternal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7166-5232
Peter DregerInternal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7429-8570

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41559396
PMCPMC13056524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.